36. The pharmaceutical composition of any of claims 29 to 35, wherein hCG is administered for at least 12 weeks.

37. The pharmaceutical composition of any of claims 29 to 36, wherein hCG is administered subcutaneously.

38. The pharmaceutical composition of any of claims 29 to 37, which is used simultaneously, sequentially or separately with an antiestrogen.

39. The pharmaceutical composition of claim 38, wherein the antiestrogen is Tamoxifen.

40. The pharmaceutical composition of claim 39, wherein Tamoxifen is administered orally in a daily amount of about 30 milligrams.

41. The pharmaceutical composition of any of claims 38 to 40, which is used in combination with a Type 1 interferon.

42. The pharmaceutical composition of any of claims 29 to 41, wherein hCG is recombinant hCG.

43. The pharmaceutical composition of any of claims 29 to 41, wherein hCG is replace by a protein having the biological activity of hCG and/or a binding activity toward the hCG receptor.

44. The pharmaceutical composition of claim 43, wherein the protein is selected from the group

consisting of LH, recombinant LH, LH fusion molecules, FSH fusion molecules and TSH fusion molecules.

45. A method of inhibiting the proliferation of breast cancer cells, comprising administering a host in need thereof an effective inhibiting amount of hCG.

46. A method of inhibiting the proliferation of breast cancer cells in postmenopausal women, comprising administering a host in need thereof an effective inhibiting amount of hCG.

47. A method of inhibiting the proliferation of metastatic mammary tumor cells, comprising administering a host in need thereof an effective inhibiting amount of hCG.

48. A method of inhibiting the proliferation of metastatic mammary tumor cells in postmenopausal women, comprising administering a host in need thereof an effective inhibiting amount of hCG.

49. The method of any of claims 45 to 48, comprising additionally administering an effective inhibiting amount of an antiestrogen.

50. The method of claim 49, comprising additionally administering a Type 1 interferon to the host.

51. The method of any of claims 45 to 50, wherein hCG is replaced by a protein having the biological activity of hCG and or a binding activity toward an hCG receptor.

52. The method of claim 51, wherein the protein is selected from the group consisting of LH, recombinant LH, LH fusion molecules, FSH fusion molecules and TSH fusion molecules.

53. An article of manufacture comprising a container, in which is contained a pharmaceutical composition according to any of claims 29 to 44, and which comprises a label stating the use of the pharmaceutical composition for the treatment of breast cancer.